Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
PR Newswire•30/09/2026•16:30 ET
1
Key Highlights
- ➤Castle Biosciences (CSTL) enrolled 2,799 patients across 29 U.S. centers.
- ➤Low-risk i31-SLNB patients had 22.8% observed SLN positivity after biopsy.
- ➤Eligible patients avoiding SLNB had five-year RFS of 99.6%.
- ➤Transected melanomas showed 93.2% versus 64.1% five-year RFS for Class 1A versus 2B.
- ➤Early-stage Class 2B patients had 73.7% five-year RFS, similar to stage IIB.
Expert Statements
Joseph Gadzia, Study author and board-certified dermatologist and Mohs micrographic surgeon at Kansas Medical Center
“Staging is an essential starting point, but understanding a patient's tumor biology can help us make more informed recommendations about sentinel lymph node biopsy and follow-up care.”
Joseph Gadzia, Study author and board-certified dermatologist and Mohs micrographic surgeon at Kansas Medical Center
“Seeing excellent outcomes among patients with low-risk i31-SLNB results who did not undergo SLNB in this large, prospective study should give physicians greater confidence in using DecisionDx-Melanoma results to help guide these important decisions with their patients.”
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management PR Newswire
Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6%
Get started
Create a free account to read the full story.